Quanta Pharma Retatrutide 30mg is a triple agonist peptide that activates GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation.

Why not try our SerenQ Retatrutide Pens?

Pre-mixed and ready to use – no reconstitution needed 🔥 Currently on sale!

20mg – £140

40mg – £210

Included Free

+ 3ml Bacteriostatic Water with order

Quanta Pharma Retatrutide 30mg

is a pharmaceutical-grade

triple agonist peptide

targeting GLP-1, GIP, and glucagon receptors simultaneously. This lyophilised vial from

Quanta Pharma

offers researchers a high-purity compound for advanced metabolic and weight management studies. The 30mg dosage provides an ideal starting point for research protocols. Available for

UK delivery

with fast dispatch.

Quanta Pharma Retatrutide 30mg Specifications

Peptide

Retatrutide

Type

Triple Agonist

Dosage

30mg/vial

Form

Lyophilised

Half-Life

~6 Days

Storage

2-8°C

Retatrutide 30mg

Quanta Pharma

Quanta Pharma Retatrutide Research Benefits

Triple receptor action

Superior weight management

Enhanced fat oxidation

Glycemic control

Extended half-life

How Quanta Pharma Retatrutide Works

Quanta Pharma Retatrutide

is a

triple agonist peptide

that simultaneously activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the Glucagon receptor. This unique triple-action approach sets it apart from all other incretin-based peptides.

The GLP-1 and GIP receptor activation enhances insulin secretion, reduces appetite, and slows gastric emptying. The addition of Glucagon receptor agonism is what makes

Quanta Pharma Retatrutide

truly unique, as it directly stimulates fat oxidation, increases energy expenditure, and promotes hepatic fat reduction. This three-pronged approach delivers superior metabolic effects in research settings.

Quanta Pharma Retatrutide vs Tirzepatide vs Semaglutide

Semaglutide

targets only the GLP-1 receptor.

Tirzepatide

activates both GLP-1 and GIP receptors.

Quanta Pharma Retatrutide

goes further by targeting all three receptors: GLP-1, GIP, and Glucagon. Clinical research has demonstrated that this triple agonist approach produces the most significant weight reduction results of any incretin-based compound studied to date, making

Quanta Pharma Retatrutide

the most advanced option for metabolic research.

Why Choose Quanta Pharma Retatrutide 30mg?

Quanta Pharma

is renowned for producing pharmaceutical-grade peptides with exceptional purity and accurate dosing. The 30mg vial of

Quanta Pharma Retatrutide

provides an accessible entry point for research protocols, while maintaining the same quality standards as the larger 50mg variant. Each vial undergoes rigorous quality control to ensure consistency and reliability.

⚠️ FOR LABORATORY RESEARCH USE ONLY

NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE

Safety Classification:

Legal Notice:

This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.